Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Fulgent Genetics, Inc. before investing.

In this article, we go over a few key elements for understanding Fulgent Genetics, Inc.’s stock price such as:

• Fulgent Genetics, Inc.’s current stock price and volume
• Why Fulgent Genetics, Inc.’s stock price changed recently
• Upgrades and downgrades for FLGT from analysts
• FLGT’s stock price momentum as measured by its relative strength

About Fulgent Genetics, Inc. (FLGT)

Before we jump into Fulgent Genetics, Inc.’s stock price, history, target price and what caused it to recently dip, let’s take a look at some background.

Fulgent Genetics, Inc. provides clinical diagnostic and therapeutic development solutions to physicians and patients in the United States and internationally. The company’s clinical diagnostic solutions include molecular diagnostic testing; genetic testing; anatomic pathology laboratory tests and testing services, such as gastrointestinal pathology, dermatopathology, urologic pathology, breast pathology, neuropathology, and hematopathology; oncology tests and testing services; and sequencer services related to hereditary cancer, reproductive health, and other diseases. Its therapeutic development solutions focus on developing drug candidates for treating a range of cancers using a nanoencapsulation and targeted therapy platform to enhance the therapeutic window and pharmacokinetic profile of new and existing cancer drugs. The company operates picture genetics platform, which includes gene probes, data suppression and comparison algorithms, adaptive learning software, and proprietary laboratory information management systems that helps customers to identify health markers in their personal DNA. It serves insurance, hospitals, medical institutions, other laboratories, governmental bodies, payors, large corporations, and patients. Fulgent Genetics, Inc. was formerly known as Fulgent Diagnostics, Inc. and changed its name to Fulgent Genetics, Inc. in August 2016. The company was founded in 2011 and is headquartered in El Monte, California.

Want to learn more about Fulgent Genetics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Fulgent Genetics, Inc..

Fulgent Genetics, Inc.’s Stock Price as of Market Close

As of July 31, 2026, 4:00 PM, CST, Fulgent Genetics, Inc.’s stock price was $16.550.

Fulgent Genetics, Inc. is down 18.11% from its previous closing price of $20.210.

During the last market session, Fulgent Genetics, Inc.’s stock traded between $16.050 and $17.510. Currently, there are approximately 30.88 million shares outstanding for Fulgent Genetics, Inc..

Fulgent Genetics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Fulgent Genetics, Inc. Stock Price History

Fulgent Genetics, Inc.’s (FLGT) price is currently down 19.35% so far this month.

During the month of July, Fulgent Genetics, Inc.’s stock price has reached a high of $21.590 and a low of $16.050.

Over the last year, Fulgent Genetics, Inc. has hit prices as high as $31.040 and as low as $13.460. Year to date, Fulgent Genetics, Inc.’s stock is down 37%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Fulgent Genetics, Inc. Stock’s Price to Dip?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

One of the most common factors that can drastically impact a stock’s price is analyst upgrades and downgrades. When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. However, as of July 30, 2026,, no analysts have changed their rating of Fulgent Genetics, Inc.’s stock over the last month.

Additionally, you'll want to evaluate Fulgent Genetics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Fulgent Genetics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Fulgent Genetics, Inc.’s current valuation based on AAII’s Value Grade is a A, which means it is considered to be Deep Value.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Fulgent Genetics, Inc. (FLGT) by visiting AAII Stock Evaluator.

Relative Price Strength of Fulgent Genetics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of July 30, 2026, Fulgent Genetics, Inc. has a weighted four-quarter relative price strength of 9.62%, which translates to a Momentum Score of 81 and is considered to be Very Strong.

Want to learn more about how Fulgent Genetics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Fulgent Genetics, Inc. Stock Price: Bottom Line

As of July 31, 2026, Fulgent Genetics, Inc.’s stock price is $16.550, which is down 18.11% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Fulgent Genetics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.